After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.
Hologic posts solid Q4 gains with earnings and revenue beat, margin expansion, and a buyout deal by Blackstone and TPG.
Hologic (HOLX) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.01 per share a year ago.
Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Investors with an interest in Medical - Instruments stocks have likely encountered both Hologic (HOLX) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
HOLX's fiscal Q4 2025 earnings may face limits as macro pressures and slow Diagnostics curb momentum.
The maker of women's health products rejected a $16 billion offer from the parties in May.
Hologic (HOLX) reached $68.5 at the closing of the latest trading day, reflecting a +2.24% change compared to its last close.
Hologic's GYN Surgical segment gains momentum internationally as expanded fibroid treatments support growth.
HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.